

## **Morgan Stanley Third Annual Global Healthcare Unplugged Conference May 4 - 6, 2005**

### **IMPORTANT US REGULATORY DISCLOSURES ON COVERED COMPANIES**

The following analyst, strategist, or research associate (or a household member) owns securities in a company that he or she covers or recommends: Nancy Yu - Pfizer Inc (common stock), Merck & Co. (common stock); Jami Rubin - GlaxoSmithKline (common stock), Pfizer Inc (common stock). Morgan Stanley policy prohibits research analysts, strategists and research associates from investing in securities in their sub industry as defined by the Global Industry Classification Standard ("GICS," which was developed by and is the exclusive property of MSCI and S&P). Analysts may nevertheless own such securities to the extent acquired under a prior policy or in a merger, fund distribution or other involuntary acquisition.

As of March 31, 2005, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in this report: Novo Nordisk, GlaxoSmithKline Pharma, Health Mgmt. Associates, Incyte Corporation, Amylin Pharmaceuticals, AmerisourceBergen, Celgene Corp., Gilead Sciences, Neurocrine Biosciences Inc., Allergan Inc., NPS Pharmaceutical, Onyx Pharmaceuticals, AtheroGenics, Eyetech Pharmaceuticals, ImClone Systems, MedImmune, Bausch & Lomb Inc., Chiron Corporation, GlaxoSmithKline, Aetna, Epigenomics, Roche, St. Jude Medical, Patterson Companies, Regeneron, Vertex Pharmaceuticals, Triad, The Medicines Company, OSI Pharmaceuticals, Shire Pharma Group, PacifiCare Health Systems, Sepracor, Pfizer Inc.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering of securities of Amylin Pharmaceuticals, Henry Schein, Inc., Barrier Therapeutics, Cubist Pharmaceuticals, Idenix Pharmaceuticals, Inspire Pharmaceuticals, Inc., AtheroGenics, Eyetech Pharmaceuticals, ImClone Systems, Advanced Medical Optics, Bausch & Lomb Inc., Chiron Corporation, Merck & Co., Amgen, Epigenomics, Pharmion, Vicuron, Triad, OSI Pharmaceuticals, Sepracor, Pfizer Inc.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Basilea Pharmaceutica, Health Net, Inc., Henry Schein, Inc., Beckman Coulter, Biovail, Alexion Pharmaceuticals, Barrier Therapeutics, Cubist Pharmaceuticals, Idenix Pharmaceuticals, Inspire Pharmaceuticals, Inc., Allergan Inc., NPS Pharmaceutical, Onyx Pharmaceuticals, AtheroGenics, Eyetech Pharmaceuticals, ImClone Systems, CYTYC Corporation, Advanced Medical Optics, Chiron Corporation, Abbott Laboratories, Eli Lilly, Forest Labs, Biomet, Merck & Co., Amgen, Aetna, Actelion, Epigenomics, Smith & Nephew, Pharmion, Vicuron, Triad, The Medicines Company, OSI Pharmaceuticals, Renal Care Group Inc., PacifiCare Health Systems, Sepracor, Pfizer Inc.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Basilea Pharmaceutica, Novo Nordisk, Baxter International, Community Health Systems, King Pharmaceuticals, Medicis, Lexicon Genetics Inc., Beckman Coulter, Biovail, Alexion Pharmaceuticals, Barrier Therapeutics, Cubist Pharmaceuticals, Idenix Pharmaceuticals, Inspire Pharmaceuticals, Inc., AmerisourceBergen, Celgene Corp., Gilead Sciences, Neurocrine Biosciences Inc., Allergan Inc., NPS Pharmaceutical, Onyx Pharmaceuticals, AtheroGenics, Eyetech Pharmaceuticals, ImClone Systems, Becton Dickinson, Boston Scientific, Genentech, deCODE genetics, CYTYC Corporation, Advanced Medical Optics, MedImmune, Bausch & Lomb Inc., Chiron Corporation, Humana Inc., Johnson & Johnson, Abbott Laboratories, Eli Lilly, Forest Labs, Biomet, Merck & Co., Amgen, GlaxoSmithKline, Aetna, Actelion, Epigenomics, Roche, Qiagen NV, Serono, Stryker Corporation, Wilson Greatbatch, Zimmer Holdings, Inc., QLT Inc., Smith & Nephew, Pharmion, Vicuron, St. Jude Medical, Patterson Companies, Regeneron, Vertex Pharmaceuticals, The Medicines Company, OSI Pharmaceuticals, Shire Pharma Group, WellPoint, Inc., Renal Care Group Inc., PacifiCare Health Systems, Sepracor, Pfizer Inc.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from GlaxoSmithKline Pharma, Humana Inc., Johnson & Johnson, Abbott

Laboratories, Eli Lilly, Forest Labs, Biomet, Merck & Co., Amgen, GlaxoSmithKline, Aetna, Roche, Pfizer Inc.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following companies covered in this report: Basilea Pharmaceutica, Novo Nordisk, Baxter International, Community Health Systems, King Pharmaceuticals, Medicis, Lexicon Genetics Inc., Health Net, Inc., Henry Schein, Inc., Beckman Coulter, Biovail, Alexion Pharmaceuticals, Barrier Therapeutics, Cubist Pharmaceuticals, Idenix Pharmaceuticals, Inspire Pharmaceuticals, Inc., AmerisourceBergen, Celgene Corp., Gilead Sciences, Neurocrine Biosciences Inc., Allergan Inc., NPS Pharmaceutical, Onyx Pharmaceuticals, AtheroGenics, Eyetech Pharmaceuticals, ImClone Systems, Becton Dickinson, Boston Scientific, Genentech, deCODE genetics, CYTYC Corporation, Advanced Medical Optics, MedImmune, Bausch & Lomb Inc., Chiron Corporation, Humana Inc., Johnson & Johnson, Abbott Laboratories, Eli Lilly, Forest Labs, Biomet, Merck & Co., Amgen, GlaxoSmithKline, Aetna, Actelion, Epigenomics, Roche, Qiagen NV, Serono, Stryker Corporation, Wilson Greatbatch, Zimmer Holdings, Inc., QLT Inc., Smith & Nephew, Pharmion, Vicuron, St. Jude Medical, Patterson Companies, Regeneron, Vertex Pharmaceuticals, Triad, The Medicines Company, OSI Pharmaceuticals, Shire Pharma Group, WellPoint, Inc., Renal Care Group Inc., PacifiCare Health Systems, Sepracor, Pfizer Inc.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following companies covered in this report: GlaxoSmithKline Pharma, HCA, Inc., Becton Dickinson, Boston Scientific, Genentech, deCODE genetics, CYTYC Corporation, Advanced Medical Optics, MedImmune, Bausch & Lomb Inc., Chiron Corporation, Humana Inc., Johnson & Johnson, Abbott Laboratories, Eli Lilly, Forest Labs, Biomet, Merck & Co., Amgen, GlaxoSmithKline, Aetna, Epigenomics, Roche, WellPoint, Inc., Renal Care Group Inc., PacifiCare Health Systems, Sepracor, Pfizer Inc.

The research analysts, strategists, or research associates principally responsible for the preparation of this research report have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Morgan Stanley & Co. Incorporated makes a market in the securities of Incyte Corporation, Amylin Pharmaceuticals, Lexicon Genetics Inc., Henry Schein, Inc., Alexion Pharmaceuticals, Barrier Therapeutics, Cubist Pharmaceuticals, Idenix Pharmaceuticals, Inspire Pharmaceuticals, Inc., Celgene Corp., Gilead Sciences, Neurocrine Biosciences Inc., NPS Pharmaceutical, Onyx Pharmaceuticals, AtheroGenics, Eyetech Pharmaceuticals, ImClone Systems, deCODE genetics, CYTYC Corporation, MedImmune, Chiron Corporation, Biomet, Amgen, Priority Healthcare, QLT Inc., Pharmion, Vicuron, Patterson Companies, Regeneron, Vertex Pharmaceuticals, The Medicines Company, OSI Pharmaceuticals, Shire Pharma Group, Sepracor.

Morgan Stanley & Co. International Ltd. is a corporate broker to Shire Pharma Group.